Neumora Halts Lead Depression Drug, Cuts 35% Staff, Extends Cash Runway to Q3 2027
NMRA sits 28% above its 52-week low of $0.716 on elevated volume (12× avg).
Summary
Neumora Therapeutics has discontinued development of its lead antidepressant, navacaprant, after two late-stage trials failed to meet primary endpoints. This significant setback led to a 35% workforce reduction. These actions, following the news and 8-K filed yesterday, are expected to extend the company's cash runway into Q3 2027, a material improvement from the 12-month runway reported in the Q1 2026 10-Q. The company will now focus its resources on other pipeline candidates: NMRA-511, NMRA-898, and NMRA-215. Data for NMRA-511's MAD cohort is expected Q4 2026, with Phase 2b guidance by year-end, while NMRA-898 Phase 1 data is due H2 2026.
At the time of this announcement, NMRA was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.4M. The 52-week trading range was $0.72 to $3.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.